
Does it excite you to build something from the ground up, and do you have deep expertise in peptide process chemistry and leading high-performing teams? If this sounds like you, and you are ready to shape the future of peptide drug substance development at a fast-growing biotech, then you could be our new colleague.
Your new position Zealand Pharma is looking for a Global Head of Drug Substance – Senior Director, based in Boston. This is a rare opportunity to establish and lead a Peptide Process Development function from the ground up — building a Boston-based lab and team while providing global leadership across Drug Substance. The role owns the full arc from synthetic route scouting through Phase 1 and 2, laying the foundation for Phase 3-ready processes, and is central to enabling Zealand's growing pipeline of peptide therapeutics to reach patients.
We offer exciting responsibilities:
Your profile The ideal candidate brings a track record of scientific excellence in peptide process chemistry combined with the leadership presence to inspire and grow a team. A pragmatic problem-solver and strategic thinker, this person thrives in a dynamic, build-phase environment and can balance hands-on technical depth with cross-functional influence. Comfort with ambiguity and a bias for action are essential.
Your new team This role leads a globally distributed Drug Substance organization spanning two sites. In Boston, the role will establish a process wet lab staffed with process scientists focused on hands-on peptide process development and optimization. In Copenhagen, a DS team serves as the primary connection point to CMOs, ensuring alignment on manufacturing strategies, technology transfer, and day-to-day CMO oversight. Together, the two teams form a cohesive global function with complementary responsibilities, working in close partnership with colleagues across Research, Analytical Development, and Manufacturing.
Let's bond and be bold We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture.
Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation. Join us and let's bond and be bold.
Interested in bonding with us? Then please apply as soon as possible. The applications will be reviewed as they come in. While a cover letter is not required, please include a few sentences in your CV explaining your motivation for applying.
We are committed to an inclusive recruitment process and welcome applications from all job applicants.
About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data-driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma-invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com
#LI-onsite

At Zealand Pharma, we are a Danish biotechnology company on a mission to change lives with next generation peptide medicines.
In our effort to reach our goals, bonding is at the core of everything we do. Let it be discovering and developing the best new peptide drugs for patients, engaging with partners or connecting with each other.
Ten drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market. Our current pipeline of internal product candidates focuses on obesity, chronic inflammation, and certain rare diseases.
Our leading obesity programs are backed by strong partners, including Roche and Boehringer Ingelheim.
We are based in Copenhagen (Søborg), Denmark, with a team in the U.S. For further information about our business and activities, please visit www.zealandpharma.com or bond with us through LinkedIn.